Trial Profile
A retrospective study evaluating Sofosbuvir-based direct acting antiviral therapy of recurrent HCV infection following liver transplant
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2018
Price :
$35
*
At a glance
- Drugs Sofosbuvir (Primary) ; Daclatasvir; Ledipasvir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 06 Nov 2018 New trial record
- 10 Oct 2018 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018